DrugPatentWatch Archives
Click here to return to the current data set
|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and more than 2,300 generic ingredients from more than 1,700 branded and generic pharmaceutical companies, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Generic Name: chloroquine phosphate
Summary for Generic Name: chloroquine phosphate
| |||||||||||||
Clinical Trials for: chloroquine phosphateStudy of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial) Status: Recruiting Condition: Carcinoma, Intraductal, Noninfiltrating; DCIS; Ductal Carcinoma In Situ A Phase 1 Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine Status: Completed Condition: Malaria A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects Status: Completed Condition: Malaria Prophylaxis Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung Cancer Status: Not yet recruiting Condition: Small Cell Lung Cancer Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients Status: Not yet recruiting Condition: Small Cell Lung Cancer Chloroquine Population Pharmacokinetics in Pre and Post-partum Women Status: Recruiting Condition: Vivax Malaria Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly Status: Active, not recruiting Condition: Hyper-reactive Malarial Splenomegaly; Malaria; Anaemia Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis Status: Not yet recruiting Condition: Malaria, Falciparum; Chloroquine; Azithromycin; Immunization Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD) Status: Recruiting Condition: Vivax Malaria Study on the Treatment of Vivax Malaria Status: Recruiting Condition: Vivax Malaria Courtesy of ClinicalTrials.org See more clinical trials for this drug | |||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Patent Expiration | Exclusivity Expiration | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Synthelabo | ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE | chloroquine phosphate; primaquine phosphate | Tablet; Oral | 014860 | Approved prior to Jan 1, 1982 | DISCN | No | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Impax Labs | CHLOROQUINE PHOSPHATE | chloroquine phosphate | Tablet; Oral | 080880 | Approved prior to Jan 1, 1982 | RX | No | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Md Pharm | CHLOROQUINE PHOSPHATE | chloroquine phosphate | Tablet; Oral | 087228 | Approved prior to Jan 1, 1982 | DISCN | No | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Purepac Pharm | CHLOROQUINE PHOSPHATE | chloroquine phosphate | Tablet; Oral | 080886 | Approved prior to Jan 1, 1982 | DISCN | No | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc